BioMarin Pharmaceutical Receives CRL from FDA, Sarepta Therapeutics Surges

January 14, 2016 5:00 PM

23 0

BioMarin Pharmaceutical Receives CRL from FDA, Sarepta Therapeutics Surges

BioMarin announced that it has received FDA’s CRL for Kyndrisa; stock of its competitor, Sarepta, surged

BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) disclosed that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) with regard to its New Drug Application (NDA) for Kyndrisa. The drug is used to treat Duchenne muscular dystrophy amenable to exon 51 skipping.

Read more

To category page

Loading...